Keynote Forum: Accelerating Global Innovation with China's Efficiency

• Biomedicine as an emerging pillar industry in China

• Global Frontier of Biomedical Innovation

• The Road to MNC: Evolution of Chinese Pharmaceutical Enterprises

• FIC and World-Class Drug Development

• China’s R&D Efficiency and the Continuous Evolution of Innovative Drugs

• CPIC Major Announcements

• CPIC Award Ceremony

China Novel Drug Frontier Technology

• CNS Novel Drug R&D Session

• ATMP & CGT Global Expansion Session

• Next-Generation AAV Innovation & Advancement Special Session

• Stem Cell and Regenerative Medicine New Technology Session

• Patient-Centric Stem Cell New Drug R&D Innovation Practice Session

• Advanced Stem Cell Culture Technology Session

• In-Vivo CAR-T and Cellular Therapy Session

• Global Session on Small Nucleic Acid Drug Innovation

• Global Innovation of Antibodies and ADCs session

• R&D Strategies for Developing Innovative Drug Molecules Session

• Innovative Small Molecule Chemical Drugs Session

• Peptide Drug R&D Frontier Session

• Next-Generation Innovative Therapies Breakthrough Session

• Organoid and Biochip Session

• The Booming Radiopharmaceuticals Session

• Anti‑Tumor Drug Development Session

• Nanobody Drug R&D Session

• Innovations in Exosome Therapeutics Session

• Non‑clinical Assessment of Novel High‑Potential Drugs

AI-Driven Healthcare Industry

• Future-Driven Intelligent R&D–AI for Life Science and Drug Discovery

• AI for Science Reshaping Innovative Drug R&D Session

• Computing Power × Mental Power × R&D Power: New Paradigms of Innovative Drug R&D in the AI Era Session

• AI Reshaping the End-to-End Clinical R&D Session

• The Era of Superintelligent Agents for Chinese Innovative Drugs

• Panel Discussion: AI-Empowered Four-in-One Translation Platform

• AI-Driven Innovation Practices in Pharmaceutical Enterprises

• AI·Intelligent Transformation: From Data Foundation to Scenario Value

• Entering the New Era of AI in Biopharma

Policy Regulation and Intellectual Property Compliance

• Decree No. 818 and a New Era for the Development of Biomedicine Industry session

• IIT Supervision Model and China’s Innovation Efficiency Session

Pharmaceutical Production and Supply Chain Management

• Antibody and ADC Drug Intelligent Manufacturing Session

• Build Innovation & Collaborative Ecosystem for Biopharma Supply Chain

Medicine-Engineering Integration and Innovative Medical Devices

• Brain-Computer Interface Session

• International Advanced Drug Delivery Systems / Drug-Device Combinations Session

Investment, Financing, IPO and M&A

• Industrial Securities Session: Ushering in a New Era of Precision Oncology

• Soochow Pharma Special Session: Diversified Payment Models and Global Competitiveness of Innovative Drugs

• Cross-border Investment Session

• The Evolution and Beyond of NewCo Session

• China Healthcare M&A Session

• Embracing a New Era of Pharma BD

Cross-Border Cooperation and China’s New Drug Global Expansion

• China–U.S. Collaboration Forum: Accelerating Global Drug Development Through Chinese Innovation

• Global Development of Pharma Enterprises and Emerging Market Cooperation

• BRICS Session: Deepening Presence in Diverse Global Markets, Delivering the Full-Chain Value of Innovative Chinese Drugs

• China-Europe Healthcare Industry Meeting

• China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies

• Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises

• Clinical Development of Next-Generation Innovative Oncology Drugs

• From IP to BD: China Innovative Drug Transaction Competency

• Workshop: The Key to Win Biotech Global BD Deals

• Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3

• Collaboration Between North American and Chinese Innovative Drug Industries

• Biosimilars Commercialization & Global Launch Session（China Focus）

• Protheragen Session: Global Biomedical Cross-Border Transactions

• Vaccine Innovation and Global Expansion

• Hong Kong Global Opportunities Session

• Capital Strategies and Hong Kong IPOs for Biopharmaceutical Enterprises

• U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session

Innovation Ecosystem and Models

• The Path to Innovation and Transformation for Traditional Pharmaceutical Companies

• Biopharmaceutical Industrial Park Development Session

• Clinical Innovation and Translation in China: Innovation Begins at the Bedside

• USTC/China‑Japan Pharmaceuticals&New Materials Innovation Session – Original Innovation Power from USTC

• Biotech Innovation Ecosystem Transformation Session

• CPIC Roadshow Session

• Bio-Link Capital Roadshow Session